Biovail Suffers One-Two Punch In Wellbutrin XL Feud

Law360 (August 2, 2006, 12:00 AM EDT) -- In a setback for Canada’s Biovail Corp. in the ongoing legal battle over its blockbuster drug Wellbutrin XL, a federal judge on Tuesday granted Anchen Pharmaceuticals Inc. a key part of a summary judgment motion that will allow the generic maker to produce a copycat version of the antidepressant.

U.S. District Judge James V. Selna of the U.S. District Court for the Central District of California said in court documents this week that Anchen’s generic version of Wellbutrin XL, a once-daily pill used to treat depression,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.